The National Institute for Health and Care Excellence (NICE) has recommended brentuximab vedotin combined with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with untreated stage 3 or 4 CD30+ Hodgkin lymphoma.
The decision is based on findings from the phase 3 ECHELON-1 trial, which demonstrated improved survival outcomes for patients receiving brentuximab vedotin plus AVD compared to the current ABVD multi-agent chemotherapy standard.
Professor Graham Collins, Associate Professor and Consultant Haematologist at Oxford University Hospitals NHS Foundation, said: “The recent positive NICE recommendation of brentuximab vedotin + AVD as a treatment option for adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma represents a major advance in the frontline management of Hodgkin lymphoma for our patients.”…
